A PYMNTS Company

EU: Mylan purchase of Abbot generics approved

By  |  January 28, 2015

The European Commission approved on Wednesday the acquisition of Abbot Laboratories by the U.S. based producer of generic pharmaceuticals Mylan Inc, subject to conditions.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    “The decision is conditional upon the divestment of a number of Mylan’s businesses in Germany, the United Kingdom, France,Ireland and Italy,” the Commission said.

    Generic drugmaker Mylan Inc agreed in July to buy Abbott’s branded specialty and generics business in developed markets outside the United States in a $5.3 billion deal that will bolster its product line and also cut its tax bill.

    Full Content: The Street

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.